Simultaneous determination of 8 beta-lactams and linezolid by an ultra-performance liquid chromatography method with UV detection and cross-validation with a commercial immunoassay for the quantification of linezolid

Abstract

Linezolid and beta-lactams are anti-infective drugs frequently used in intensive care unit patients. Critical illness could induce alterations of pharmacokinetic parameters due to changes in the distribution, the metabolism and the elimination process. Therapeutic drug monitoring (TDM) is therefore recommended to prevent mainly under-dosing of beta-lactams or hematological and neurological toxicities of linezolid. In Multi-or Extensively-Drugs Resistant-Tuberculosis Bacteria, the regimen could include linezolid with meropenem and amoxicillin/clavulanate justifying the development of a method allowing their simultaneous quantification.The aim of this work was to develop an in-house ultra-performance liquid chromatography method with UV detection (UHPLC-PDA) allowing the simultaneous determination of 8 beta-lactams (amoxicillin, aztreonam, cefepime, ceftazidime, ceftriaxone, cefuroxime, meropenem and piperacillin) and linezolid and to crossvalidate the linezolid quantification with a new commercial immunoassay (ARK kit) tested on a Cobas analyzer. The main advantages of the immunoassay are a 24/24 h random access assay which is fully automated and results provided within 2 h.The interference due to potential co-administrated drugs was evaluated on both methods. The preanalytical factors (type of matrix, stability) for linezolid were also investigated. The influence of hemolysis, icteria or lipemia on the spectroscopic detection of the immunoassay was assessed. The analytical performances were evaluated using the accuracy profiles approach with acceptance limits fixed at ±30%. Seventy patient samples were measured using both methods.No cross-reaction with the tested anti-infective drugs as well as no influence of hemolysis, lipemia, icteria were observed. The linezolid concentration could be measured on heparinized plasma or serum without a significant difference and remained stable for at least 72h at 4 • C.The UHPLC-PDA method performed well in the analytical range investigated (0.25-50 mg/L for meropenem, 0.75-50 mg/L for linezolid and 1-200 mg/L for other beta-lactams) with an intermediate precision and a relative bias below 7.6 and 7.7%, respectively. The analytical range of the immunoassay was narrower, from 0.85 to 18.5 mg/L. The precision and relative bias were lower than 8.1% and 4.2%, respectively. Results obtained on clinical samples showed an acceptable difference between methods with a mean bias of -1.8% [95% confidence interval: -5.2% -1.6%].To conclude, both methods showed acceptable performance to perform TDM of linezolid considering the therapeutic through target of 2-8 mg/L. The choice of the method should be made according to the degree of emergency of the response required and the field of application justifying or not the simultaneous quantification of beta-lactams and linezolid.

Electrochemiluminescence Sensor Based on N-Doped Carbon Quantum Dots for Determination of Ceftazidime in Real Samples

“…The radical scavenging properties of pyridinium ions have proved by earlier studies. 57 Thus, here the pyridinium moiety of CFZ reacts with N-CQD •− and prevents the formation of excited states leading to the quenching of ECL.…”

Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients—A Narrative Review

“…Several companies have developed methods of ready-to-use kits for the quantitative analysis of several antibiotics, including beta-lactams, in plasma. However, since instrumentation in different laboratories vary, the method transfer is more complicated and time-consuming than with the previously described immunoassay methods [ 67 ]. The low throughput of the analyzers is another disadvantage of the chromatographic methods.…”

“How to” guide for pharmacist‐led implementation of beta‐lactam therapeutic drug monitoring in the critically ill

“…16 At program inception, there were no Food and Drug Administration approved immunoassays for BL antibiotics available in the U.S. and only one which was CE-marked in Europe (Ark Diagnostics Inc., Fremont, California). 24 Concurrent with efforts to secure approval from clinical practice stakeholders and leadership, we began to develop local LC-MS/MS assays to determine total serum drug concentrations for three BL antibiotics commonly utilized in the treatment of the critically ill at Mayo Clinic-cefepime, piperacillin/tazobactam, and meropenem. The process by which these assays were developed adhered to CLIA standards and has been described in detail in a previous publication.…”